The DeGregorio Family Foundation for Gastric and Esophageal Cancer is pleased to announce our 4th annual funding opportunity for gastroesophageal malignancies. The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. We support high quality, innovative, and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, as well as epidemiologic studies may also be supported.
Funding Period: January 1, 2014 – December 31, 2015
Amount: $250,000 for entire grant period. The IDC rate is 10% ($225,000 direct, $25,000 indirect).
Eligibility: Investigators must be associated with an academic or medical institution possessing a tax-exempt status under section 501 (c)(3) of the IRS code. Research projects must not be funded currently under a separate mechanism.
Research projects are selected through a rigorous review process, and project goals
must align with The DeGregorio Family Foundation’s mission. The Foundation’s application review process is guided by its Scientific Advisory Board. Criteria for successful grants are impact, likelihood of completion and making a significant contribution to understanding, diagnosis, or treating gastric or esophageal malignancies. The intention of this award is to provided seed funding for research in upper GI malignancies. Funded applicants are expected to apply for subsequent peer reviewed support (i.e. NIH or similar agency).
Funding will be divided into three installments. The first installment will be provided when appropriate institutional approvals are submitted and the study is underway. The 2nd installment is contingent upon submission and review of an interim report at 1 year, and the final installment will be contingent on receipt of a final study report.
Any publications or presentations resulting from this research must be acknowledged.
Make an impact with your 26.2 miles. Guaranteed Entry: The TCS New York City Marathon will take place..
Gastric cancer is the 4th most common cancer worldwide with a 5 year survival rate of only 20%. The research..
We gathered on Saturday morning for a bagel breakfast to support the team DeGregorio runners in today’s..
Copyright © 2014. All Rights Reserved.
Visit us at Facebook